The Asian Cardiovascular Market Outlook to 2014: Regional and therapeutic analysis, pipeline impact and growth opportunities

Published by: Business Insights

Published: Mar. 22, 2009 - 244 Pages

Table of Contents

Executive Summary

Patient potential

Regional healthcare and licensing trends

Regional market analysis

Key players in the Asian cardiovascular market

Chapter 1 Scope and methodology

Scope

Key CV sub-therapy areas covered in this report

Methodology

Chapter 2 Patient potential

Summary

Introduction

Disease description

Defining patient potential

Limitations of cardiovascular epidemiology data

Cardiovascular risk factors

Hypertension

Dyslipidemia

Diabetes

Cardiovascular disease

Acute thrombotic events

Acute coronary syndrome

Venous thromboembolism

Stroke

Chapter 3 Regional healthcare and licensing trends

Summary

Introduction

Regional healthcare expenditure

Healthcare financing

The external environment

Licensing analysis

Chapter 4 Regional market analysis

Summary

Introduction

Leading cardiovascular therapy areas

Leading Asian cardiovascular markets

Leading cardiovascular brands

Antihypertensives

Introduction

Leading antihypertensive brands

Regional dynamics

Market analysis by drug class

Calcium channel blockers: driven by replacability

Angiotensin receptor blockers: driven by efficacy

ACE inhibitors: downplayed by side effects

Beta-blockers: driven by pricing

Diuretics: outdated and stabilizing

Antihypertensives sales forecasts

Anti-dyslipidemics

Introduction

Leading anti-dyslipidemic brands

Regional dynamics

Market analysis by drug class

Statins: irreplacable dominance

Fibrates: outdated

Other anti-dyslipidemics

Anti-dyslipidemics sales forecast

Cardiac therapies

Introduction

Leading cardiac therapy brands

Market analysis by drug class

Nitrates/nitrites: driven by pricing

Anti-arrhythmics: overcome by nitrates

Others

Cardiac therapies sales forecasts

Anti-thrombotics

Introduction

Leading anti-thrombotic brands

Regional dynamics

Market analysis by drug class

Heparins/low molecular weight heparins: overshadowed by antiplatelets

Vitamin K antagonists: outdated

Oral anti-platelets: preventive advantage drives sales

Fibrinolytics: driven by emergency care demands

Anti-thrombotic sales forecasts

Chapter 5 Key players in the Asian cardiovascular market

Summary

Introduction

Key events and trends

Global CV research affected by ‘Lipitorphobia’; diffused impact on Asia

From a single wheeled to multi-wheeled structure: reducing dependence on the CV sector, target Asia

HDL mimetics will minimally drive the Asian market

Asian market shares

Pfizer: contemplating a paradigm shift

Country focus

Therapy focus

Key brands

Pipeline

Apixaban

Cardiovascular portfolio sales forecasts

Sanofi-Aventis

Country focus

Therapy focus

Key brands

Pipeline

Multaq

Cardiovascular portfolio sales forecasts

AstraZeneca

Country focus

Therapy focus

Key brands

Pipeline

Ticagrelor

Cardiovascular portfolio sales forecasts

Novartis

Country focus

Therapy focus

Key brands

Pipeline

Tekturna

Cardiovascular portfolio sales forecasts

Merck & Co

Country focus

Therapy focus

Key brands

Pipeline

Anacetrapib

Cardiovascular portfolio sales forecasts

Bayer

Country focus

Therapy focus

Key brands

Pipeline: Xarelto to capture Lovenox market

Xarelto

Cardiovascular portfolio sales forecasts

GSK

Country focus

Therapy focus

Key brands

Pipeline

Letairis

Cardiovascular portfolio sales forecasts

Servier

Country focus

Therapy focus

Key brands

Pipeline

Cardiovascular portfolio sales forecasts

Roche

Country focus

Therapy focus

Key brands

Pipeline

Dalcetrapib

Cardiovascular portfolio sales forecasts

Boehringer Ingelheim

Country focus

Therapy focus

Key brands

Pipeline

Cardiovascular portfolio sales forecasts

Forecast rankings of the key players, 2014

Chapter 6 Appendix

IMS Data

C1 Cardiac therapy

C2 Antihypertensives

C3 Diuretics

C4 Cerebral and peripheral vasotherapeutics

C5 Antivaricosis/anti-haemorrhoidal preparations

C6 Other cardiovascular products

C7 Beta-blocking agents

C8 Calcium antagonists

C9 Agents acting on the renin-angiotensin system

C10 Lipid-regulating/anti-atheroma preparations

C11 Cardiovascular multitherapy combination products

B1 Anti-thrombotic agents

B2 Antifibrinolytics, antidotes to anti-coagulants, inhibitors, blood coagulation and haemostyptics

B3 Anti-anaemic preparations

B6 All other haematological agentsGlossary

Glossary

Index

List of Figures

Figure 2.1: Relationship between CV disease and risk factors

Figure 2.2: Risk factors associated with hypertension

Figure 3.3: External analysis of the Asian region

Figure 3.4: Asian CV licensing trends, 2007

Figure 4.5: Competitive dynamics of therapy areas in the Asian CV market,

Figure 4.6: Competitive dynamics of the 10 major Asian markets,

Figure 4.7: Competitive dynamics of the Asian antihypertensive market by drug class, 2006-07

Figure 4.8: Regional dynamics of the Asian antihypertensive market, 2006-07

Figure 4.9: Regional dynamics of the Asian CCB market, 2006-07

Figure 4.10: Regional dynamics of the Asian ARB market, 2006-07

Figure 4.11: Regional dynamics of the Asian ACE inhibitor market, 2006-07

Figure 4.12: Regional dynamics of the Asian beta-blocker market, 2006-07

Figure 4.13: Regional dynamics of the Asian diuretics market, 2006-07

Figure 4.14: Competitive dynamics in the Asian anti-dyslipidemics market, 2006-07

Figure 4.15: Regional dynamics of the Asian anti-dyslipidemics market, 2006-07

Figure 4.16: Regional dynamics of the Asian statins market, 2006-07

Figure 4.17: Regional dynamics of the Asian fibrate market, 2006-07

Figure 4.18: Competitive dynamics in the Asian cardiac therapies market by drug class, 2006-07

Figure 4.19: Regional dynamics of the Asian cardiac therapies market, 2006-07

Figure 4.20: Competitive dynamics in the Asian anti-thrombotic market by drug class, 2006-07

Figure 4.21: Regional dynamics of the Asian anti-thrombotics market, 2006-07

Figure 5.22: Big Pharma’s strategy for the future

Figure 5.23: Competitive dynamics of key players in the Asian CV market, 2006-07

Figure 5.24: Focus therapy areas and revenue shares of Pfizer, 2007

Figure 5.25: Major events/trends in Pfizer’s forcasted growth dynamics

Figure 5.26: Focus therapy areas and revenue shares of Sanofi-Aventis, 2007

Figure 5.27: Major events/trends in Sanofi-Aventis’s forcasted growth dynamics

Figure 5.28: Focus therapy areas and revenue shares of AstraZeneca, 2007

Figure 5.29: Ticagrelor DISPERSE trial results

Figure 5.30: Major events/trends in AstraZeneca’s forcasted growth dynamics

Figure 5.31: Focus therapy areas and revenue shares of Novartis, 2007

Figure 5.33: Major events/trends in Novartis’s forcasted growth dynamics

Figure 5.34: Focus therapy areas and revenue shares of Merck, 2007

Figure 5.36: Major events/trends in Merck & Co’s forcasted growth dynamics

Figure 5.37: Focus therapy areas and revenue shares of Bayer, 2007

Figure 5.38: Xarelto Phase III top-line data

Figure 5.39: Major events/trends in Bayer’s forcasted growth dynamics

Figure 5.40: Focus therapy areas and revenue shares of GSK, 2007

Figure 5.41: Major events/trends in GSK’s forcasted growth dynamics

Figure 5.42: Focus therapy areas and revenue shares of Servier, 2007

Figure 5.43: Major events/trends in Servier’s forcasted growth dynamics

Figure 5.44: Focus therapy areas and revenue shares of Roche, 2007

Figure 5.45: Dalcetrapib Phase II trial data

Figure 5.46: Major events/trends in Roche’s forcasted growth dynamics

Figure 5.47: Focus therapy areas and revenue shares of Boehringer Ingelheim, 2007

Figure 5.48: Major events/trends in Boehringer Ingelheim’s forcasted growth dynamics

List of Tables

Table 2.1: Estimated prevalence of hypertension in the Asian region, 2007

Table 2.2: Estimated prevalence of hypertension in the Asian region,

Table 2.3: Interpretation of blood lipid levels

Table 2.4: Estimated prevalence of hypercholesterolemia in the Asian region, 2007

Table 2.5: Estimated forecast prevalence of hypercholesterolemia in the Asian region, 2008-14

Table 2.6: Estimated prevalence of diabetes in the Asian region, 2007

Table 2.7: Estimated prevalence of diabetes in the Asian region, 2008-14

Table 2.8: Estimated prevalence of major CV diseases in the Asian region, 2007

Table 2.9: Estimated incidence of myocardial infarction (MI) in the Asian region, 2007

Table 2.10: Estimated incidence of DVT in the Asian region, 2007

Table 2.11: Estimated prevalence of stroke in the Asian region, 2007

Table 3.12: Recent statistics on the healthcare sector in the Asian region, 2006

Table 3.13: Public and private financing in 10 Asian markets, 2005

Table 3.14: Sales of types of CV brands in the 10 major markets of the Asian region, 2007

Table 4.15: Breakdown of the Asian CV market by major therapeutic areas, 2006-07

Table 4.16: CV sales by therapy area across the Asian region, 2007

Table 4.17: Top five leading CV drug classes across 10 major Asian and global markets, 2007

Table 4.18: Top 10 Asian CV brands, 2006-07

Table 4.19: Top five leading brands across the 10 major Asian and global markets, 2007

Table 4.20: Breakdown of Asian antihypertensive market by drug class, 2006-07

Table 4.21: Breakdown of the Asian antihypertensive market by leading brands, 2006-08

Table 4.22: Market share of the leading classes of antihypertensives drugs in the Asian region, 2007

Table 4.23: Breakdown of the CCB class in the Asian market by leading brands, 2006-07

Table 4.24: Breakdown of the ARB drug class in the Asian market by leading brands, 2006-07

Table 4.25: Breakdown of the ACE inhibitor class in the Asian market by leading brands, 2006-07

Table 4.26: Breakdown of the beta-blocker class in the Asian market by leading brands, 2006-07

Table 4.27: Breakdown of the diuretics class in the Asian market by leading brands, 2006-07

Table 4.28: Sales forecasts for antihypertensive drug classes in the major markets of the Asian region, 2008-14

Table 4.29: Breakdown of Asian antihypertensive market by drug class, 2006-07

Table 4.30: Breakdown of the Asian antihypertensive market by leading brands, 2006-07

Table 4.31: Market share of the leading classes of anti-dyslipidemic drugs in the Asian region, 2007

Table 4.32: Breakdown of the statins class in the Asian market by leading brands, 2006-07

Table 4.33: Sales forecasts for dyslipidemia drug classes in the Asian region, 2008-14

Table 4.34: Breakdown of Asian cardiac therapies market by drug class, 2006-07

Table 4.35: Breakdown of the cardiac therapies class in the Asian market by leading brands, 2006- 07

Table 4.36: Sales forecasts for cardiac therapies drug classes in the Asian region, 2004-10

Table 4.37: Breakdown of Asian anti-thrombotics market by drug class, 2006-07

Table 4.38: Breakdown of the Asian anti-thrombotics market by leading brands, 2006-07

Table 4.39: Breakdown of the oral anti-platelets class in the Asian market by leading brands, 2006-07

Table 4.40: Sales forecast for the anti-thrombotic drug class in the Asian region, 2008-14

Table 4.41: Key players in the Asian CV market, 2006-07

Table 5.42: Top five companies across the 10 major Asian and global markets, 2007

Table 5.43: Key asian markets for Pfizer, 2007

Table 5.44: Pfizer’s marketed Asian CV portfolio, 2006-07

Table 5.45: Pfizer’s CV R&D pipeline, 2008

Table 5.46: An overview of Apixaban

Table 5.47: Forecast sales for Pfizer’s Asian CV portfolio, 2008-14

Table 5.48: Key asian markets for Sanofi-Aventis, 2007

Table 5.49: Sanofi-Aventis’s marketed Asian CV portfolio, 2007

Table 5.50: Sanofi-Aventis’s late stage CV R&D pipeline, 2008

Table 5.51: An overview of Multaq

Table 5.52: Multaq Phase III trial results

Table 5.53: Forecast sales for Sanofi-Aventis’s Asian CV portfolio, 2008-14

Table 5.54: Key asian markets for AstraZeneca, 2007

Table 5.55: AstraZeneca’s marketed Asian CV portfolio, 2006-07

Table 5.56: Sanofi-Aventis’ late stage CV R&D pipeline, 2008

Table 5.57: An overview of ticagrelor

Table 5.58: Forecast sales for AstraZeneca’s Asian CV portfolio, 2008-14

Table 5.59: Key asian markets for Novartis, 2007

Table 5.60: Novartis’s marketed Asian CV portfolio, 2006-07

Table 5.61: Novartis’s late stage CV R&D pipeline, 2009

Table 5.62: An overview of Tekturna/Rasilez

Table 1.1: ASPIRE HIGHER Phase III trial series

Table 5.63: Forecast sales for Novartis’s Asian CV portfolio, 2008-14

Table 5.64: Key asian markets for Merck & Co, 2007

Table 5.65: Merck & Co’s marketed Asian cardiovascular portfolio, 2006-07

Table 5.66: Merck’s late stage CV R&D pipeline, 2008

Table 5.67: An overview of Anacetrapib

Table 5.68: Forecast sales for Meck & Co’s Asian CV portfolio, 2008-14

Table 5.69: Key asian markets for Bayer, 2007

Table 5.70: Bayer’s marketed Asian cardiovascular portfolio, 2007

Table 5.71: Bayer’s cardiovascular R&D pipeline, 2008

Table 5.72: An overview of Xarelto

Table 5.73: Forecast sales for Bayer’s Asian cardiovascular portfolio, 2008-14

Table 5.74: Key asian markets for GlaxoSmithKline, 2007

Table 5.75: GSK’s marketed Asian cardiovascular portfolio, 2007

Table 5.76: GSK’s cardiovascular R&D pipeline, 2008

Table 5.77: An overview of Letairis

Table 5.78: Forecast sales for GSK’s Asian cardiovascular portfolio, 2008-14

Table 5.79: Key asian markets for Servier, 2007

Table 5.80: Servier’s marketed Asian cardiovascular portfolio, 2007

Table 5.81: Forecast sales for Servier’s Asian CV portfolio, 2008-14

Table 5.82: Key asian markets for Roche, 2007

Table 5.83: Roche’s marketed Asian cardiovascular portfolio, 2007

Table 5.84: Roche’s cardiovascular R&D pipeline, 2008

Table 5.85: Forecast sales for Roche’s Asian CV portfolio, 2008-14

Table 5.86: Key asian markets for Boehringer Ingelheim, 2007

Table 5.87: Boehringer Ingelheim’s marketed Asian cardiovascular portfolio, 2007

Table 5.88: Forecast sales for Boehringer Ingelheim’s Asian CV portfolio, 2008-14

Table 5.89: Comparative ranking of key players in 2007 - 2014

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.